BioNTech-JPM Presentation 2026 WEBSITE version 1.pdf

1、Prof.Dr.Ugur Sahin,M.D.,CEO&Co-Translating Science into Survivalfounder,BioNTech44th J.P.Morgan Healthcare ConferenceJanuary 13,20262This Slide Presentation Includes Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigatio

2、n Reform Act of 1995,as amended,including,but not limited to,statements concerning:BioNTechs expected revenues and net profit/(loss)related to sales of BioNTechs COVID-19 vaccine,referred to as COMIRNATY where approved for use under full or conditional marketing authorization,in territories controll

3、ed by BioNTechs collaboration partners,particularly for those figures that are derived from preliminary estimates provided by BioNTechs partners;the rate and degree of market acceptance of BioNTechs COVID-19 vaccine and,if approved,BioNTechs investigational medicines;the initiation,timing,progress,r

4、esults,and cost of BioNTechs research and development programs,including BioNTechs current and future preclinical studies and clinical trials,including statements regarding the expected timing of initiation,enrollment,and completion of studies or trials and related preparatory work and the availabil

5、ity of results,and the timing and outcome of applications for regulatory approvals and marketing authorizations;BioNTechs expectations regarding potential future commercialization in oncology,including goals regarding timing and indications;the targeted timing and number of additional potentially re

6、gistrational trials,and the registrational potential of any trial BioNTech may initiate;discussions with regulatory agencies;BioNTechs expectations with respect to intellectual property;the impact of BioNTechs collaboration and licensing agreements,including BioNTechs partnership with BMS;the develo